Binding and activity of the prostacyclin receptor (IP) agonists, treprostinil and iloprost, at human prostanoid receptors: Treprostinil is a potent DP1 and EP2 agonist
Open Access
- 1 July 2012
- journal article
- research article
- Published by Elsevier BV in Biochemical Pharmacology
- Vol. 84 (1), 68-75
- https://doi.org/10.1016/j.bcp.2012.03.012
Abstract
No abstract availableKeywords
Funding Information
- United Therapeutics Corporation, North Carolina, United States
This publication has 50 references indexed in Scilit:
- Treatment of pulmonary arterial hypertension: The role of prostacyclin and prostaglandin analogsRespiratory Medicine, 2011
- How has epoprostenol changed the outcome for patients with pulmonary arterial hypertension?International Journal of Clinical Practice, 2010
- Beraprost Sodium, an Orally Active Prostaglandin I2 Analog, Improves Renal Anemia in Hemodialysis Patients With Peripheral Arterial DiseaseTherapeutic Apheresis and Dialysis, 2010
- Treprostinil Sodium (Remodulin), a Prostacyclin Analog, in the Treatment of Critical Limb Ischemia: Open-Label StudyVascular, 2006
- The Prostacyclin Analog, Treprostinil Sodium, Provides Symptom Relief in Severe Buerger’s DiseaseAngiology, 2006
- The Prostacyclin Analogue Beraprost Sodium Prevents Occlusion of Bypass Grafts in Patients with Lower Extremity Arterial Occlusive Disease: A 20-Year Retrospective StudyAnnals of Vascular Surgery, 2005
- Prostacyclin and its analogues in the treatment of pulmonary hypertensionPharmacology & Therapeutics, 2004
- Long-Term Treatment of Primary Pulmonary Hypertension with Aerosolized Iloprost, a Prostacyclin AnalogueNew England Journal of Medicine, 2000
- A Comparison of Continuous Intravenous Epoprostenol (Prostacyclin) with Conventional Therapy for Primary Pulmonary HypertensionNew England Journal of Medicine, 1996
- Prostacyclin-induced acute pulmonary vasodilation in primary pulmonary hypertension.Cell Metabolism, 1982